Drug or treatment

Chimeric antigen receptor clinical trials

• 102Clinical trials
• 2New in 30 days
• 23Countries

Newest trials

All recruiting trials (102)

• CAR-T Therapy Safety, Response, and Immune-Escape: Observational Study in Adults

  This observational study looks at adults who receive CAR-T cell therapy or bispecific antibodies to see which factors predict response and immune-related side effects.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07915102

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• CD19 CAR-T Therapy for Kids with Refractory Childhood SLE

  This study tests whether a patient’s own CD19 CAR-T cells can help children and young adults with severe, hard-to-treat lupus.

  Recruiting Phase 1 Seoul National University Hospital · Seoul · NCT07855302

• In vivo circular RNA CAR T cell therapy for adults with relapsed or refractory B-cell lymphomas

  A one-arm, dose-escalation study tests a circular RNA CAR T cell therapy in adults with relapsed or refractory CD19-positive B-cell cancers to see if it is safe and tolerable and to get early signs of benefit.

  Recruiting Phase 1 Ruijin Hospital · Shanghai, Shanghai Municipality and 1 other locations · NCT07774572

• CAR-T Cell Therapy for B-ALL (relapsed/refractory)

  This trial tests a patient’s own CAR-T cells to treat relapsed or refractory B-cell ALL in people aged 5–50.

  Recruiting Early Phase 1 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi · NCT07695012

• IgPro20 in adults with immune deficiencies after CAR T-cell or T-cell redirecting therapies

  This study tests IgPro20 in adults with secondary immune deficiency after CAR T-cell or T-cell redirecting therapies to see if it lowers serious bacterial infections.

  Recruiting at 2 sites Phase 3 CSL Behring · Orange, California and 59 other locations · NCT07648264

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

• CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers

  This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07584889

• Dual-target CD22/CD19 CAR-T consolidation after first remission in high-risk B-ALL

  This test will try a dual-target CD22/CD19 CAR-T cell treatment as consolidation for patients with high-risk B-cell acute lymphoblastic leukemia who are in their first remission.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07575971

• CD22/CD19 CAR-T consolidation for adults with standard-risk B-ALL

  This study will try dual-target CD22/CD19 CAR-T cell therapy as a consolidation treatment for adults with standard-risk B-cell acute lymphoblastic leukemia who are in first remission.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07575919

• TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults

  This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07572136

• Pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma

  This phase 1 study tests whether pomalidomide, given after CD19 CAR T-cell therapy, is safe and may help people whose CD19+ B-cell leukemia or lymphoma has come back or not responded.

  Recruiting Phase 1 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07532525

• Autologous B7-H3 CAR T Cells in Advanced Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  This study tests a patient’s own B7-H3 CAR T cells to see if they can help people 18 and older whose small cell lung cancer or EPNEC has come back or hasn’t responded to prior treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07509034

• NexCAR19 (Talikabtagene Autoleucel) for relapsed or refractory B‑cell leukemias and lymphomas

  This trial will test modified versions of a patient's own T cells (NexCAR19/Talikabtagene Autoleucel) to see if they can control relapsed or refractory B‑cell leukemias and lymphomas in adults.

  Recruiting at 3 sites Phase 2/3 Health Institutes of Turkey · Ankara and 3 other locations · NCT07502118

• CD19 CAR-T versus donor lymphocyte infusion for clearing MRD after allogeneic stem cell transplant in Ph-negative B-ALL

  This trial tests whether a single infusion of autologous CD19 CAR-T cells or chemotherapy plus donor lymphocyte infusion better clears minimal residual disease in patients aged 3–79 with Ph-negative B‑cell ALL after allogeneic stem cell transplant.

  Recruiting Phase 3 Peking University People's Hospital · Beijing, China · NCT07441291

• GCAR1 CAR-T therapy for GPNMB-expressing solid tumours

  This study tests different doses of GCAR1 CAR-T cells in people with specific cancers that make high levels of the GPNMB protein to see if the treatment is safe and how it affects the cancer.

  Recruiting at 3 sites Phase 1 Canadian Cancer Trials Group · Calgary, Alberta and 3 other locations · NCT07297667

• BAFF-R CAR-T therapy for relapsed or refractory BAFF-R–positive B-cell lymphoma

  This trial will test whether a BAFF‑R–targeted CAR‑T cell therapy is safe and can help adults with relapsed or refractory BAFF‑R–positive B‑cell lymphomas (such as DLBCL, CLL, FL, MCL, or WM).

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07259070

• Asciminib maintenance after alloHCT or CAR T for adults with Ph+ ALL

  Doctors will try asciminib in adults with Ph+ ALL who are in remission after an allogeneic stem cell transplant or CAR T therapy to check safety and find the best dose to help prevent relapse.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07250087

• In vivo CAR-T therapy for relapsed or refractory B‑cell leukemias, lymphomas, and multiple myeloma

  This trial will try a single in‑body (intravenous) CAR‑T infusion to treat adults with relapsed or refractory B‑cell acute lymphoblastic leukemia, B‑cell non‑Hodgkin lymphoma, or multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07239323

• Bispecific B7H3/IL13Ra2 armored CAR-T therapy for recurrent or refractory glioblastoma

  This trial will try giving repeated intraventricular injections of EPC-003 bispecific CAR-T cells to adults with B7H3 and/or IL13Ra2 positive recurrent or refractory glioblastoma to see if it is safe and helps control the tumor.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07193628

• GPC3-targeted CAR T cells armored with IL-15 and IL-21 for pediatric non‑CNS solid tumors

  This treatment will try personalized CAR T cells that target GPC3 and are engineered to make IL‑15 and IL‑21 in children and young adults with relapsed or refractory non‑CNS solid tumors that express GPC3.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT07148050

• Autocrine p40 CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell lymphoma

  This will test a dual-targeting CD19/CD20 autocrine p40 CAR-T cell treatment in adults whose B-cell lymphoma has returned or not responded to prior therapies.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07097207

• GPC2-targeted CAR T cell therapy for relapsed or refractory medulloblastoma in children and young adults

  This trial will test whether autologous GPC2-targeted CAR T cells delivered into the brain ventricle are safe and active for children and young adults with relapsed or refractory medulloblastoma or similar CNS embryonal tumors.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT07087002

• CD19-directed CAR T cells with IL-7Rα signaling for children with relapsed or refractory B-cell ALL

  We will test whether a child's own T cells, changed to target CD19 and boost IL‑7 signaling, can safely treat children aged 1–18 with relapsed or refractory B-cell acute lymphoblastic leukemia.

  Recruiting Phase 1 Chulalongkorn University · Bangkok, Bangkoknoi and 2 other locations · NCT07078929

• Brain scans and blood tests to spot neurotoxicity after CAR T-cell therapy

  This project will try brain MRIs, cognitive tests, and blood biomarkers to see if we can identify which adults receiving CAR T-cell therapy will develop neurotoxicity (ICANS).

  Recruiting University of California, San Diego · La Jolla, California · NCT07075523

• Fecal transplant to restore gut microbiome before CAR T therapy for relapsed or refractory B‑cell lymphoma

  This trial will test whether a fecal microbiome transplant can restore healthy gut bacteria and improve outcomes for adults with relapsed or refractory CD19 B‑cell lymphoma who received high‑risk antibiotics and are receiving CAR T‑cell therapy.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07042438

• Using immunoglobulin to help patients with low antibody levels after CAR T cell therapy

  This study is testing if giving immunoglobulin to patients with low antibody levels after CAR T cell therapy can help prevent infections and improve their quality of life.

  Recruiting University of Alberta · Edmonton, Alberta · NCT06989541

• Treatment of recurrent high-grade gliomas using anti-GARP CAR T cell therapy

  This study is testing a new type of CAR T cell therapy to see if it can safely help people with recurring high-grade gliomas fight their tumors better.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06964737

• Spinal injections of cytarabine, methotrexate, and hydrocortisone to prevent severe CAR T neurotoxicity

  This phase II test tries whether giving intrathecal cytarabine, methotrexate, and hydrocortisone around day 4 (with a day 7 hydrocortisone if no symptoms) can prevent severe neurotoxicity in adults receiving Yescarta or Tecartus CAR T-cell therapy.

  Recruiting Phase 2 OHSU Knight Cancer Institute · Portland, Oregon · NCT06895473

• Treatment of advanced liver cancer using a targeted T cell injection

  This study is testing a new type of T cell injection to see if it can safely help people with advanced liver cancer that has a specific marker called GPC3.

  Recruiting Phase 1 Peking University · Beijing, Beijing Municipality and 1 other locations · NCT06891742

• Nanobody-based CAR-T therapy for relapsed B-cell leukemia

  This study is testing a new type of CAR-T therapy to see if it can help people with relapsed B-cell leukemia who haven't had success with other treatments.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06880913

• CAR-T cell therapy for children with relapsed leukemia or lymphoma

  This study is testing a new CAR-T cell therapy to see if it can help children with relapsed leukemia or lymphoma feel better and improve their chances of recovery.

  Recruiting Hong Kong Children's Hospital · Hong Kong · NCT06866873

• FGFR4-directed CAR T cell therapy for children and young adults with recurrent or refractory rhabdomyosarcoma

  This trial will try a personalized CAR T cell treatment that targets the FGFR4 protein for people aged 3–39 whose rhabdomyosarcoma has returned or not responded after at least two prior treatments.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06865664

• Odronextamab with CAR T‑cell therapy for relapsed or refractory diffuse large B‑cell lymphoma

  This trial tests whether giving odronextamab before or after CAR T‑cell therapy helps adults with diffuse large B‑cell lymphoma that has relapsed or not responded to prior treatments.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06854159

• GPC3-targeted CAR T cell therapy for recurrent GPC3-positive glioblastoma

  This study will try CAR T cells engineered to target GPC3 in adults with recurrent GPC3-positive glioblastoma during their planned surgery.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT06815432

• Using genetically modified immune cells to treat recurrent brain tumors

  This study is testing a new treatment using modified immune cells to see if it can help people with recurring brain tumors feel better and fight their cancer.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06815029

• BCMA-CD19 CAR-T therapy for autoimmune diseases

  This study is testing a new CAR-T cell therapy to see if it can help adults with tough autoimmune diseases feel better and improve their health.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06794008

• Using CAR-NK cells to treat autoimmune diseases like lupus and nephrotic syndrome

  This study is testing a new treatment using CAR-NK cells to see if it can help people with autoimmune diseases like lupus and nephrotic syndrome feel better.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT06792799

• Evaluating CHT102 for treating advanced solid tumors with mesothelin expression

  This study is testing a new immune therapy called CHT102 to see if it can help adults with advanced solid tumors that have the mesothelin protein and haven't responded to other treatments.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06717022

• Using CAR T cells to treat children with hard-to-treat solid tumors

  This study is testing a new type of immune cell treatment for children with hard-to-treat solid tumors to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1 Chulalongkorn University · Bangkok, Pathumwan · NCT06612645

• FH-FOLR1 CAR T-cell therapy for children with relapsed or refractory AML

  This trial will test FH-FOLR1 CAR T cells in children aged six and under whose FOLR1-positive acute myeloid leukemia has returned or not responded to treatment.

  Recruiting Phase 1 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06609928

• CAR-T cell therapy targeting BCMA for treating multiple myeloma

  This study is testing a new CAR-T cell therapy that targets a specific protein to see if it can help people with hard-to-treat multiple myeloma feel better.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06581640

• Dose-escalation of CD19/CD22/BCMA CAR‑T for relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial will try a CAR‑T therapy that targets CD19, CD22, and BCMA in people with relapsed or refractory B‑cell non‑Hodgkin lymphoma to find a safe dose.

  Recruiting Early Phase 1 Shanghai Cell Therapy Group Co.,Ltd · Shanghai, Shanghai Municipality · NCT06446128

• Using modified T cells to treat T Cell Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat T cell Non-Hodgkin Lymphoma.

  Recruiting at 2 sites Phase 1 Vittoria Biotherapeutics · New York, New York and 1 other locations · NCT06420089

• Using CD22 CAR T Cells after CD19 CAR T Cells for B Cell Leukemia

  This study is testing if giving CD22 CAR T-cell therapy to children and young adults with tough-to-treat B-cell leukemia after they’ve had another CAR T-cell treatment can be safe and effective.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06408194

• Treatment for Chronic Lymphocytic Leukemia using modified T cells

  This study is testing a new treatment using modified T cells to see if it can help people with chronic lymphocytic leukemia that hasn't responded to other therapies.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06364423

• Treatment for relapsed small cell lung cancer using CAR-T therapy

  This study is testing a new CAR-T therapy for people with relapsed small cell lung cancer to see if it can help them after other treatments have failed.

  Recruiting Phase 1 Sichuan University · Chengdu, Sichuan · NCT06348797

• Treatment using CAR-T cells targeting B7-H3 for triple-negative breast cancer

  This study is testing a new CAR-T cell treatment aimed at a specific target for people with hard-to-treat triple-negative breast cancer to see if it is safe and how much can be given.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06347068

• Observational study on CAR-T therapy for lymphoma in Italy

  This study looks at how well CAR-T therapy works and its side effects for people with lymphoma in Italy by tracking their health over three years.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT06339255

• Using modified T cells to treat recurrent ovarian cancer

  This study is testing a new treatment using modified immune cells to see if it can help people with recurrent ovarian cancer that hasn't responded to standard treatments.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06305299

• KYV-101 CAR T therapy for adult dermatomyositis

  This study is testing a new CAR T therapy called KYV-101 to see if it can help adults with dermatomyositis who haven't found relief from regular treatments.

  Recruiting at 2 sites Phase 1 Stanford University · Palo Alto, California and 1 other locations · NCT06298019

• Using CMV-specific T cells to treat HIV/AIDS

  This study is testing a new treatment using specially designed T cells to see if they can help people with HIV live better while they are on their regular medication.

  Recruiting at 2 sites Early Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06252402

• IL-15 and IL-21–armored GPC3-CAR T cell therapy for adults with GPC3-positive solid tumors

  This trial tests whether CAR T cells engineered to target GPC3 and fortified with IL-15 and IL-21 can treat adults with GPC3-positive liver and other solid tumors.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT06198296

• Anti-CD19 CAR T-Cell Therapy for Refractory Myasthenia Gravis

  This study is testing a new CAR T-cell therapy to see if it can help adults with tough-to-treat myasthenia gravis feel better.

  Recruiting at 22 sites Phase 2/3 Kyverna Therapeutics · Los Angeles, California and 21 other locations · NCT06193889

• Treatment using modified T-cells for relapsed or refractory B-cell cancers

  This study is testing a new treatment that uses specially modified T-cells to see if it can help people with hard-to-treat B-cell cancers.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06191887

• CAR T-cell therapy for treating relapsed multiple myeloma

  This study is testing a new type of immune therapy called OriCAR-017 to see if it can help people with relapsed multiple myeloma feel better and improve their treatment outcomes.

  Recruiting at 2 sites Phase 1/2 OriCell Therapeutics Co., Ltd. · Hangzhou, Zhejiang and 4 other locations · NCT06182696

• Anti-CD19 CAR-T for non-relapsing progressive multiple sclerosis

  This Phase 1 trial will test whether a single infusion of KYV-101 (anti-CD19 CAR-T cells) is safe and can slow worsening in adults with non-relapsing progressive MS.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06138132

• Using modified T cells to treat relapsed head and neck cancer

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed head and neck cancer feel better and improve their outcomes.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06096038

• Using engineered T cells to treat advanced sarcoma in young patients

  This study is testing if special T cell treatments can help young patients with advanced sarcoma who haven't had success with regular treatments.

  Recruiting Phase 1 Instituto de Investigación Hospital Universitario La Paz · Madrid · NCT06087341

• CAR-T cell therapy to help highly sensitized patients receive kidney transplants

  This study is testing if CAR T cell therapy can help highly sensitized patients who have been waiting for a kidney transplant by reducing their antibodies and making it easier for them to receive a transplant.

  Recruiting at 3 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Boston, Massachusetts and 2 other locations · NCT06056102

• Geriatric assessment to improve recovery after CAR-T therapy for older patients with blood cancers

  This study is testing if personalized support and therapy can help older patients with blood cancers recover better after receiving CAR-T treatment.

  Recruiting at 4 sites Phase 2 City of Hope Medical Center · Duarte, California and 3 other locations · NCT06052826

• Combining CAR T-cell therapy with radiation for relapsed follicular lymphoma

  This study is testing if combining a new CAR T-cell therapy with radiation can help people with relapsed follicular lymphoma feel better and have fewer side effects.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06043323

• Using CAR NK cells to treat systemic lupus erythematosus

  This study is testing a new type of immune cell treatment to see if it can safely help people with moderate to severe lupus who haven't responded well to other treatments.

  Recruiting Early Phase 1 Changhai Hospital · Shanghai · NCT06010472

• Treatment using engineered T cells for certain types of blood cancer

  This study is testing a new treatment using specially engineered T cells to see if it can help people with certain types of blood cancer that haven't responded to other treatments.

  Recruiting Phase 1 University Health Network, Toronto · Toronto, Ontario · NCT05963217

• Treatment for patients with specific types of blood cancer using engineered T-cells

  This study is testing a new treatment using specially modified T-cells to see if it can help patients with a type of blood cancer called acute myeloid leukemia that hasn't responded to other therapies.

  Recruiting at 9 sites Phase 1 AvenCell Therapeutics, Inc. · Ulm, Baden-Wurttemberg and 14 other locations · NCT05949125

• Combining pembrolizumab with CAR T-cell therapy for recurrent primary mediastinal large B-cell lymphoma

  This study is testing if adding pembrolizumab to CAR T-cell therapy can help people with recurrent primary mediastinal large B-cell lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05934448

• Treatment of aggressive large B-cell lymphoma with LYL314

  This study is testing a new CAR T-cell therapy called LYL314 to see if it can effectively treat aggressive large B-cell lymphoma in different groups of patients.

  Recruiting at 35 sites Phase 1/2 Lyell Immunopharma, Inc. · Irvine, California and 34 other locations · NCT05826535

• Long-term follow-up for patients who received CAR T-cell therapy

  This study is checking how people who had CAR T-cell therapy feel and do over the long term, by following them for up to 15 years to see if there are any lasting effects or health changes.

  Recruiting Imugene Limited · Culver City, California · NCT05822427

• CAR-T cell therapy with or without radiation for advanced prostate cancer

  This study is testing if a new CAR-T cell therapy, with or without radiation, can help people with advanced prostate cancer live longer and feel better.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05805371

• CAR T Cell Therapy for Recurrent or Refractory Acute Myeloid Leukemia

  This study is testing a new CAR T-cell therapy to see if it can help people with recurring or hard-to-treat acute myeloid leukemia by using modified immune cells to attack cancer cells.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05672147

• CAR T-cell therapy for advanced liver cancer

  This study is testing a new type of immune therapy called Ori-C101 to see if it can help people with advanced liver cancer who haven't had success with other treatments.

  Recruiting at 7 sites Phase 1/2 OriCell Therapeutics Co., Ltd. · Beijing, Beijing Municipality and 6 other locations · NCT05652920

• Combination of CAR-DC Vaccine and Immune Checkpoint Inhibitors for Treating Malignant Tumors

  This study is testing a new vaccine combined with immune treatments to see if it can help people with advanced tumors and certain types of lymphomas fight their cancer better.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT05631886

• Treatment of primary central nervous system lymphoma using modified T cells delivered into the brain

  This study is testing if giving special immune cells directly into the brain can help people with primary central nervous system lymphoma fight their cancer.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05625594

• Evaluating blood tests to monitor recovery after CAR T-cell therapy in young patients with leukemia

  This study is testing new blood tests to help doctors keep an eye on young patients with leukemia after their CAR T-cell therapy to see who might need extra treatment and who can stay healthy without it.

  Recruiting at 8 sites National Institutes of Health Clinical Center (CC) · Los Angeles, California and 7 other locations · NCT05621291

• Using a new method to create CAR T cells for treating pediatric B-ALL

  This study is testing a new way to make CAR T cells faster and safer for kids with B cell Acute Lymphoblastic Leukemia (B-ALL) to see if it helps them get better treatment more quickly.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT05480449

• B7-H3CART treatment for recurrent glioblastoma

  This study is testing a new treatment using modified immune cells to see if it can help adults with recurrent glioblastoma feel better and improve their health.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT05474378

• New CAR T-cell therapy for children and young adults with certain blood cancers

  This study is testing a new CAR T-cell therapy that uses modified cells from children's and young adults' own blood to see if it can help treat certain tough-to-treat blood cancers.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05442515

• Genetically engineered CAR T-cells for treating certain blood cancers

  This study is testing a new type of treatment using specially modified immune cells to see if they can help people with certain blood cancers that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT05418088

• Using dual-target CAR T cells to treat B cell blood cancers

  This study is testing a new type of CAR T-cell therapy that targets multiple markers to see if it can help people with tough-to-treat B cell blood cancers.

  Recruiting Phase 1 Hebei Senlang Biotechnology Inc., Ltd. · Wuhan, Hubei · NCT05388695

• Using CAR-T cells to target B7-H3 in recurrent glioblastoma

  This study is testing a new CAR-T cell therapy that targets a specific protein in patients with recurrent glioblastoma to see if it's safe and how much can be given.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT05366179

• Allogeneic CAR T-cell therapy for advanced cancers

  This study is testing a new type of immune cell therapy for people with advanced cancers to see if it can safely target and attack their tumors better than traditional treatments.

  Recruiting Phase 1 CytoMed Therapeutics Pte Ltd · Singapore · NCT05302037

• Using modified immune cells to treat platinum-resistant ovarian cancer

  This study is testing whether modified immune cells can help people with platinum-resistant ovarian cancer fight their tumors.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05225363

• CAR-GPRC5D cell therapy for people with relapsed or refractory multiple myeloma or plasma cell leukemia

  This will try a one-time CAR-T treatment called CAR-GPRC5D after short chemotherapy in adults (18–75) whose multiple myeloma or plasma cell leukemia has returned or not responded after at least three prior treatments.

  Recruiting Phase 1 Tongji Hospital · Wuhan, Hubei · NCT05219721

• Testing a new CAR T cell therapy for adolescents and adults with relapsed B-cell Non-Hodgkin Lymphoma

  This study is testing a new CAR T cell therapy to see if it can help adolescents and adults with relapsed B-cell Non-Hodgkin Lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT05098613

• Treatment for advanced non-small cell lung cancer using modified CAR-T cells

  This study is testing a new type of CAR-T cell treatment for people with advanced non-small cell lung cancer to see if it is safe and works better than standard therapies.

  Recruiting Early Phase 1 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou · NCT05060796

• New CAR-T Cell Therapy for Relapsed B-Cell Leukemia

  This study is testing a new type of CAR-T cell therapy to see if it can help people with relapsed B-cell leukemia by using their own modified immune cells after chemotherapy.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT05010564

• Using HER2 CAR T cells with checkpoint inhibitors for advanced sarcoma

  This study is testing a new treatment that combines personalized CAR T cells with immune boosters to see if it helps people with advanced HER2-positive sarcoma.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT04995003

• CD19 CAR-T cell therapy for treating relapsed B cell cancers

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed B cell cancers feel better.

  Recruiting Phase 1 Mayo Clinic · Rochester, Minnesota · NCT04892277

• Outcomes after CAR-T and radiation therapy for blood cancers

  This study looks at how combining CAR-T therapy with radiation treatment affects people with blood cancers to see if it can improve their outcomes and reduce side effects.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT04888338

• Using engineered T cells to treat pediatric solid tumors

  This study is testing a new treatment using specially modified immune cells to see if they can help children with certain types of solid tumors, like liver cancer and rhabdomyosarcoma, feel better.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT04715191

• Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04545762

• Investigating a new cell therapy for pemphigus vulgaris

  This study is testing a new cell therapy for people with pemphigus vulgaris who haven't found relief with standard treatments to see if it can help them feel better.

  Recruiting at 10 sites Phase 1/2 Cabaletta Bio · Redwood City, California and 12 other locations · NCT04422912

• Treatment using modified T cells for certain types of lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with certain types of lymphoma that haven't responded to other therapies.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT04223765

• Using GD2 CAR T cells to treat specific brain and spinal tumors in children and young adults

  This study is testing a new type of immune cell treatment for children and young adults with specific brain and spinal tumors to see if it is safe and effective.

  Recruiting Phase 1 Stanford University · Stanford, California · NCT04196413

• Treatment for relapsed or refractory CD30+ T cell lymphoma using modified T cells

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat CD30+ T cell lymphoma.

  Recruiting at 2 sites Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina and 1 other locations · NCT04083495

• Using engineered T cells to target a specific form of MUC1 in breast cancer

  This study is testing a new treatment using modified T cells to see if they can help people with advanced breast cancer by targeting a specific protein on cancer cells.

  Recruiting Phase 1 Minerva Biotechnologies Corporation · Duarte, California · NCT04020575

• CAR T-cell therapy targeting CD19 for aggressive lymphoma and leukemia

  This study is testing a new type of treatment using modified immune cells to see if it can help people with aggressive lymphoma or leukemia that hasn't responded to other treatments.

  Recruiting at 2 sites Phase 1/2 University of Alberta · Calgary, Alberta and 5 other locations · NCT03938987

• CD4-directed CAR T-cell therapy for T-cell leukemia and lymphoma

  This study is testing a new type of CAR T-cell therapy to see if it can help people with hard-to-treat T-cell leukemia and lymphoma feel better.

  Recruiting at 5 sites Phase 1 Indiana University · Miami, Florida and 5 other locations · NCT03829540

• CAR T-Cell Therapy for Neuroblastoma and Osteosarcoma

  This study is testing a new CAR T-cell therapy for children with hard-to-treat neuroblastoma and osteosarcoma to see if it can better fight their cancer while keeping them safe from serious side effects.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Atlanta, Georgia and 1 other locations · NCT03721068

• Combination of chemotherapy and immunotherapy for advanced colorectal cancer

  This study is testing if a new immune therapy combined with standard chemotherapy can help people with advanced colorectal cancer feel better and improve their treatment outcomes.

  Recruiting at 3 sites Phase 1 Celyad Oncology SA · Tampa, Florida and 3 other locations · NCT03692429

• Using modified blood cells to treat cancers that express CD70

  This study is testing if modified blood cells can help shrink tumors in patients with certain types of cancer that have CD70.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT02830724

• CD30-targeted CAR T-cell therapy for relapsed and refractory lymphomas

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Hodgkin's and Non-Hodgkin's lymphoma.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT02259556

Quick answers

How many clinical trials of Chimeric antigen receptor are recruiting right now?

102, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 23 countries. The most sites are in United States (61 trials), China (25 trials), Canada (5 trials), Italy (3 trials), Germany (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 56, Phase 1/2: 16, Phase 2: 11, Early Phase 1: 6. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →